Outcomes data for more than 400 nerve repairs
with Avance® Nerve Graft will be reviewed at hosted symposium
AxoGen, Inc. (NASDAQ: AXGN), a global leader
in developing and marketing innovative surgical solutions for
damage or discontinuity to peripheral nerves, today announced it
will participate in the 73rd Annual Meeting of the American Society
for Surgery of the Hand (ASSH). The meeting, scheduled for
September 13-15 at the Hynes Convention Center in Boston, is the
largest international gathering of hand surgeons and features
scientific sessions, training opportunities, poster presentations,
and exhibits.
AxoGen is a premier partner for the meeting and
will host a lunch symposium and panel discussion on Friday,
September 14 at 12:15 p.m. The symposium, Practical Pearls
for Adopting an Evidence-Based Nerve Repair Algorithm,
will include a discussion with three of the country’s leading nerve
surgeons. The symposium will include discussion of recent
technology and technique advances in peripheral nerve repair and
offer tips and tricks for implementing these clinically supported
algorithms, including operative efficiencies, health care
economics, and patient education. Additionally, the symposium will
feature the most current update from the RANGER® Registry.
RANGER® is the largest contemporary study in peripheral nerve
repair. The update will include the largest report to date on
outcomes data for more than 400 nerve repairs with Avance® Nerve
Graft, and will highlight outcomes on sensory, mixed, motor, and
long gap nerve repairs. In conjunction to the symposium, several
posters and presentations featuring clinical data on upper
extremity nerve repairs using Avance® Nerve Graft will be available
during the meeting.
AxoGen is sponsoring several special events throughout the
meeting that support peripheral nerve education and awareness,
including a Hand Fellows pre-course and the Women in Hand Surgery
reception. AxoGen’s comprehensive platform for nerve repair will be
featured at Booth #327. Surgeons visiting the AxoGen booth will
have the opportunity to engage in hands-on demonstrations of
Connector-Assisted Repair™ with AxoGuard® Nerve Connectors and
Avance® Nerve Graft, using microsurgery suturing and handling
techniques at a specially equipped station.
“We look forward to extending our commitment to
surgeon education and awareness through our symposium at the annual
ASSH meeting,” said Karen Zaderej, chairman, CEO, and president.
"This well-respected scientific venue provides us with a unique
opportunity to share data from our ongoing research and demonstrate
clinically supported peripheral nerve repair solutions with hand
surgeons from across the country, as well as talk with customers
about how they are using our platform for nerve repair to improve
outcomes for patients with peripheral nerve damage.”
About ASSHThe American Society for
Surgery of the Hand is the oldest medical society dedicated to the
hand and upper extremity. Its mission is to advance the science and
practice of hand and upper extremity surgery through education,
research, and advocacy on behalf of patients and practitioners. For
more information, please visit www.assh.org.
About AxoGenAxoGen (AXGN) is the
leading company focused specifically on the science, development
and commercialization of technologies for peripheral nerve
regeneration and repair. We are passionate about helping to restore
peripheral nerve function and quality of life to patients with
physical damage or discontinuity to peripheral nerves by providing
innovative, clinically proven and economically effective repair
solutions for surgeons and health care providers. Peripheral nerves
provide the pathways for both motor and sensory signals throughout
the body. Every day, people suffer traumatic injuries or undergo
surgical procedures that impact the function of their peripheral
nerves. Physical damage to a peripheral nerve, or the
inability to properly reconnect peripheral nerves, can result in
the loss of muscle or organ function, the loss of sensory feeling,
or the initiation of pain.
AxoGen's platform for peripheral nerve repair
features a comprehensive portfolio of products, including Avance®
Nerve Graft, an off-the-shelf processed human nerve allograft for
bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; AxoGuard® Nerve Connector,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; AxoGuard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
damaged peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments; and Avive® Soft
Tissue Membrane, a minimally processed human umbilical cord
membrane that may be used as a resorbable soft tissue covering to
separate tissue layers and modulate inflammation in the surgical
bed. Along with these core surgical products, AxoGen also offers
AcroVal® Neurosensory & Motor Testing System and AxoTouch®
Two-Point Discriminator. These evaluation and measurement tools
assist health care professionals in detecting changes in sensation,
assessing return of sensory, grip, and pinch function, evaluating
effective treatment interventions, and providing feedback to
patients on peripheral nerve function. The AxoGen portfolio of
products is available in the United States, Canada, the United
Kingdom, and several other European and international
countries.
Cautionary Statements Concerning
Forward-Looking Statements This Press Release contains
“forward-looking” statements as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations or predictions of future
conditions, events, or results based on various assumptions and
management's estimates of trends and economic factors in the
markets in which we are active, as well as our business plans.
Words such as “expects,” “anticipates,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” “projects,” “forecasts,”
“continue,” “may,” “should,” “will,” and variations of such words
and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our assessment on
our internal control over financial reporting, our growth, our 2018
guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:AxoGen, Inc. Kaila Krum,
VP, Investor Relations and Corporate Development
kkrum@AxoGenInc.com
Solebury Trout Brian Korb 646.378.2923
bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2023 to Mar 2024